title: Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine.
abstract: Ex vivo muscarinic receptor binding of oxybutynin and propiverine, the most commonly used anticholinergic agents for the treatment in patients with urinary incontinence, was investigated in rat tissues. The oral administration of oxybutynin (50.8 and 127 micromol/kg) caused a significant increase in the apparent dissociation constant (Kd) for specific (-)-[3H]QNB binding in the rat bladder, prostate, submaxillary gland, heart and cerebral cortex, compared with each of the control values. Also, in the submaxillary gland of these rats, there was a reduction in the maximal number of binding sites (Bmax) for (-)-[3H]QNB binding. Similarly, oral administration of propiverine at doses of 74.3-297 micromol/kg brought about a significant increase in the Kd values for (-)-[3H]QNB binding in rat tissues including the bladder, and greater increase in Kd values was seen in the rat prostate, heart and submaxillary gland. On the other hand, oral administration of propiverine, unlike oxybutynin, resulted in very little reduction in the Bmax valules for (-)-[3H]QNB binding in the submaxillary gland. In conclusion, the present study has shown that oxybutynin and propiverine, after oral administration, bind significantly to muscarinic receptors in tissues such as the bladder, which is the target organ for the treatment of urinary incontinence, and that oxybutynin appears to exhibit long-term binding to muscarinic receptors in the salivary gland.
authors.affiliation: Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Yada, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Oki
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: A
authors.initials: A
authors.lastname: Tohma
authors.forename: R
authors.initials: R
authors.lastname: Kimura
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001561:Benzilates / Q000494:pharmacology*; D008297:Male; D008333:Mandelic Acids / Q000494:pharmacology*; D010276:Parasympatholytics / Q000494:pharmacology*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism
chemical_list: D001561:Benzilates; D008333:Mandelic Acids; D010276:Parasympatholytics; D011976:Receptors, Muscarinic; C015586:propiverine; D011813:Quinuclidinyl Benzilate; C005419:oxybutynin